Evidence map›Paper›PMID 35475554›Full record

ArticleHuman mutation2022

Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease.

Andreea Chiorean, Kirsten M Farncombe, Sean Delong, Veronica Andric, Safa Ansar, Clarissa Chan, Kaitlin Clark, Arpad M Danos, Yizhuo Gao, Rachel H Giles and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Human mutation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Multiplatform curation in the development of ACMG/AMP specifications for Von Hippel-Lindau (VHL) disease.Genetics in medicine : official journal of the American College of Medical Genetics · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes.Current treatment options in oncology · 2025
    Review
  10. Familial and early recurrent pheochromocytoma in a child with a novel in-frame duplication variant ofClinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2024
    Article
  11. Developing a disease-specific annotation protocol for VHL gene curation using Hypothes.is.Database : the journal of biological databases and curation · 2023
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 4 countries.

Andreea ChioreanDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Kirsten M FarncombeToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Sean DelongDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Veronica AndricDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Safa AnsarDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Clarissa ChanDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Kaitlin ClarkDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Arpad M DanosDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Yizhuo GaoDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Rachel H GilesInternational Kidney Cancer Coalition, Duivendrecht-Amsterdam, Duivendrecht, The Netherlands.
Anna GoldenbergGenetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Payal JaniDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Kilannin KrysiakDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Lynzey KujanDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Samantha MacphersonDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Eamonn R MaherDepartment of Medical Genetics, University of Cambridge, Cambridge, UK.
Liam G McCoyDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Yasser SalamaDepartment of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada.
Jason SalibaDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Lana ShetaDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Malachi GriffithDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.
Obi L GriffithDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Washington University, St. Louis, Missouri, USA.ORCID 0000-0002-0843-4271
Lauren ErdmanGenetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Arun RamaniGenetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Raymond H KimDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0002-2147-8674
University Health Network · CAJames S. McDonnell Foundation · USHospital for Sick Children · CANetherlands Comprehensive Cancer Organisation · NLOntario Institute for Cancer Research · CAUniversity of Cambridge · GB

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision MedicineU24CA237719 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2019 to 2023
$3.8M
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome SequenR00HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2017 to 2019
$724k
DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCERK22CA188163 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2014 to 2016
$515k
INTEGRATED ANALYSIS & INTERPRETATION OF WHOLE GENOME, EXOME & TRANSCRIPTOME SEQUENCE DATA IN CANCERK99HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2015 to 2016
$264k
NCATS NIH HHS UL1 TR002345NCI NIH HHS K22 CA188163NCI NIH HHS U01 CA209936NCI NIH HHS U24 CA237719NHGRI NIH HHS K99 HG007940NHGRI NIH HHS R00 HG007940
6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome where individuals are predisposed to tumor development in the brain, adrenal gland, kidney, and other organs. It is caused by pathogenic variants in the VHL tumor suppressor gene. Standardized disease information has been difficult to collect due to the rarity and diversity of VHL patients. Over 4100 unique articles published until October 2019 were screened for germline genotype-phenotype data. Patient data were translated into standardized descriptions using Human Genome Variation Society gene variant nomenclature and Human Phenotype Ontology terms and has been manually curated into an open-access knowledgebase called Clinical Interpretation of Variants in Cancer. In total, 634 unique VHL variants, 2882 patients, and 1991 families from 427 papers were captured. We identified relationship trends between phenotype and genotype data using classic statistical methods and spectral clustering unsupervised learning. Our analyses reveal earlier onset of pheochromocytoma/paraganglioma and retinal angiomas, phenotype co-occurrences and genotype-phenotype correlations including hotspots. It confirms existing VHL associations and can be used to identify new patterns and associations in VHL disease. Our database serves as an aggregate knowledge translation tool to facilitate sharing information about the pathogenicity of VHL variants.

Indexed as

Adrenal Gland Neoplasmsvon Hippel-Lindau DiseaseGenotypeHumansMachine LearningPhenotypeVon Hippel-Lindau Tumor Suppressor ProteinVon Hippel-Lindau Tumor Suppressor ProteinCIViCgenotype-phenotypemachine learningspectral clusteringVon Hippel-Lindau

Identifiers

PMID35475554
PMCPMC9356987
OpenAlexW4224935359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.